(Total Views: 486)
Posted On: 10/07/2025 8:05:39 AM
Post# of 157772
Re: biloxiblues #157711
With only 19,000 potential patients worldwide expect Spruce Bioscience's share price to tumble back down. If Spruce is smart they will use the increased share price to sell some shares and put some money in the bank. Quite unlike a former CEO who was only interested in lining his own pockets.
A BTD for leronlimab is more likely to sustain an increased share price. Once investors realize that a BTD for leronlimab based on a combination with a PD-L1 or PD-1 inhibitor would work across multiple cancer types with an exponentially large market there would be quite a bit of excitement. A BTD for Alzheimer's would be even bigger. In either case there would be a price spike and rollback as there always is when FOMO is involved but the share price would remain relatively high.
A BTD for leronlimab is more likely to sustain an increased share price. Once investors realize that a BTD for leronlimab based on a combination with a PD-L1 or PD-1 inhibitor would work across multiple cancer types with an exponentially large market there would be quite a bit of excitement. A BTD for Alzheimer's would be even bigger. In either case there would be a price spike and rollback as there always is when FOMO is involved but the share price would remain relatively high.
(18)
(0)
